These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 31648330)
1. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Sheth VS; Potter V; Gandhi SA; Kulasekararaj AG; de Lavallade H; Muus P; Pagliuca A; Rice CFM; Mehra V; Grimaldi F; Inam S; Barber LD; Mufti GJ; Marsh JC Blood Adv; 2019 Oct; 3(20):3070-3079. PubMed ID: 31648330 [TBL] [Abstract][Full Text] [Related]
2. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells. Grimaldi F; Potter V; Perez-Abellan P; Veluchamy JP; Atif M; Grain R; Sen M; Best S; Lea N; Rice C; Pagliuca A; Mufti GJ; Marsh JCW; Barber LD Biol Blood Marrow Transplant; 2017 Feb; 23(2):293-299. PubMed ID: 27816648 [TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925 [TBL] [Abstract][Full Text] [Related]
4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
5. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. Samarasinghe S; Clesham K; Iacobelli S; Sbianchi G; Knol C; Hamladji RM; Socié G; Aljurf M; Koh M; Sengeloev H; Dalle JH; Robinson S; Van Lint MT; Halkes CJM; Beelen D; Mufti GJ; Snowden J; Blaise D; de Latour RP; Marsh J; Dufour C; Risitano AM; Am J Hematol; 2019 Jan; 94(1):80-86. PubMed ID: 30328134 [TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
7. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia]. Zhou J; Fu YW; Liang LJ; Wang Q; Han LJ; Zu YL; Zhang Y; Zhu XH; Yu FK; Fang BJ; Wei XD; Song YP Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):927-931. PubMed ID: 27916046 [No Abstract] [Full Text] [Related]
8. Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC Shah RM; Truong TH; Leaker MT; Wright NAM; Le D; Steele M; Bruce AAK; Desai S; Guilcher GMT; Lewis V Biol Blood Marrow Transplant; 2020 Oct; 26(10):1900-1905. PubMed ID: 32640311 [TBL] [Abstract][Full Text] [Related]
9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514 [TBL] [Abstract][Full Text] [Related]
10. Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Shin SH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Lee JW Bone Marrow Transplant; 2016 Nov; 51(11):1456-1463. PubMed ID: 27348538 [TBL] [Abstract][Full Text] [Related]
11. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Maury S; Balère-Appert ML; Chir Z; Boiron JM; Galambrun C; Yakouben K; Bordigoni P; Marie-Cardine A; Milpied N; Kanold J; Maillard N; Socié G; Haematologica; 2007 May; 92(5):589-96. PubMed ID: 17488681 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Ngwube A; Hayashi RJ; Murray L; Loechelt B; Dalal J; Jaroscak J; Shenoy S Pediatr Blood Cancer; 2015 Jul; 62(7):1270-6. PubMed ID: 25755151 [TBL] [Abstract][Full Text] [Related]
13. The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia. Marsh JCW; Risitano AM; Mufti GJ Biol Blood Marrow Transplant; 2019 Sep; 25(9):e277-e284. PubMed ID: 31129354 [TBL] [Abstract][Full Text] [Related]
14. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor? Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900 [TBL] [Abstract][Full Text] [Related]
15. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079 [TBL] [Abstract][Full Text] [Related]
16. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905 [TBL] [Abstract][Full Text] [Related]